Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection
Clinical and Molecular Hepatology · 2023
DOI: 10.3350/cmh.2022.0342 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, 2023. Verfasst von Chih-Lin Lin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Renai branch, Taipei City Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Hepatitis B, Chronic, Liver Neoplasms, Hepatitis B. Die Arbeit wurde bisher 96-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Taiwan University Hospital, Ministry of Health and Welfare, Ministry of Science and Technology, Taiwan.
Abstract (Originalsprache)
Hepatitis B virus (HBV) is responsible for more than 50% of hepatocellular carcinoma (HCC) in HBV hyperendemic areas, such as the Asia-Pacific region. Several hepatitis B viral factors are involved in HBV-related hepatocarcinogenesis. Hepatitis B viral load is the most important risk factor of HCC development. In addition, HBV integration, HBV genotype C, and core-promoter mutations are also associated with a risk of HCC development. For untreated chronic hepatitis B (CHB) patients, the estimated HCC incidence rates per 100 patient-years were 0.03–0.17 in inactive carriers, 0.07–0.42 in asymptomatic carriers, 0.12–0.49 in chronic hepatitis, and 2.03–3.37 in cirrhosis. Complementary to HBV DNA, serum levels of the hepatitis B surface antigen and hepatitis B core-related antigen (HBcrAg) can predict the occurrence of HCC for untreated patients with low and intermediate viral loads, respectively. For patients receiving antiviral therapy, the risks of HCC occurrence 40–60% lower than those for untreated patients. Patients treated with residual detectable HBV DNA or intrahepatic cccDNA still have a risk of HCC. Serum levels of HBcrAg, M2BPGi and fibrosis-4 are predictive of the risk of HCC development in treated patients. Several well-developed HCC risk scores can help clinicians identify high-risk CHB patients for HCC surveillance, regardless of treatment status. These strategies can help minimize the threat of HCC and prolong survival in CHB patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Renai branch, Taipei City Hospital, Taipei, Taiwan.
- Department of Psychology, National Chengchi University, Taipei, Taiwan.
- Graduate Institute of Clinical Medicine, National Taiwan University, College of Medicine, Taipei, Taiwan.
- Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Hepatitis Research Center, National Taiwan University, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Medical Research, National Taiwan University, National Taiwan University Hospital, Taipei, Taiwan.
Förderung
- National Taiwan University Hospital
- Ministry of Health and Welfare
- Ministry of Science and Technology, Taiwan
Zitieren
APA
Lin, C. L., & Kao, J. H. (2023). Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2022.0342
Vancouver
Lin CL, Kao JH. Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection. Clinical and Molecular Hepatology. 2023. doi:10.3350/cmh.2022.0342
BibTeX
@article{Lin2023,
author = {Lin, Chih-Lin and Kao, Jia-Horng},
title = {Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection},
journal = {Clinical and Molecular Hepatology},
year = {2023},
doi = {10.3350/cmh.2022.0342}
}
EUVIMED